Zheng Z M, He P J, Baker C C
Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-5055, USA.
J Virol. 1997 Dec;71(12):9096-107. doi: 10.1128/JVI.71.12.9096-9107.1997.
Alternative splicing plays an important role in regulation of bovine papillomavirus type 1 (BPV-1) gene expression. We have recently identified in BPV-1 late pre-mRNAs two purine-rich exonic splicing enhancers (SE1 and SE2) which also stimulate splicing of a Drosophila doublesex (dsx) pre-mRNA containing a suboptimal 3' splice site. In vivo studies now demonstrate that both SE1 and SE2 are required for preferential use of the BPV-1 nucleotide (nt) 3225 3' splice site in nonpermissive cells. Deletion or mutation of either element in a BPV-1 late pre-mRNA switches splicing to the late-specific alternative 3' splice site at nt 3605. To investigate the sequence specificity of these exonic splicing enhancers, various mutant SE1 or SE2 elements were connected to dsx pre-mRNAs and tested for their stimulatory effects on dsx pre-mRNA splicing in vitro. Substitution of U residues for either A or G residues in and around potential ASF/SF2 binding sites in SE1 or SE2 resulted in a significant reduction of splicing enhancer activity. However, the G-to-U substitutions in both enhancers had the largest effect, reducing splicing to near control levels. Further in vitro analyses showed that splicing enhancement by SE2 could be competed with excess unlabeled SE2 RNA, indicating that SE2 activity in HeLa nuclear extracts is mediated by trans-acting factors. UV cross-linking plus immunoprecipitation assays showed that both wild-type SE1 and SE2 RNAs could bind directly to purified HeLa SR proteins SRp30a (ASF/SF2), SRp55, and SRp75. UV cross-linking experiments also identified a 23-kDa protein which binds to SE2 but not SE1. This protein is present in both HeLa nuclear extracts and S100 extracts but absent from SR protein preparations, suggesting that it is not a classical SR protein. Mutant SE elements (containing G- to U-mutations) which had minimal splicing enhancer activity also had very weak binding capacity for these proteins, strongly suggesting that the binding of these proteins is required for splicing enhancer function.
可变剪接在调节牛乳头瘤病毒1型(BPV-1)基因表达中发挥着重要作用。我们最近在BPV-1晚期前体mRNA中鉴定出两个富含嘌呤的外显子剪接增强子(SE1和SE2),它们也能刺激含有次优3'剪接位点的果蝇双性基因(dsx)前体mRNA的剪接。体内研究现在表明,SE1和SE2都是非允许细胞中优先使用BPV-1核苷酸(nt)3225 3'剪接位点所必需的。BPV-1晚期前体mRNA中任一元件的缺失或突变都会使剪接切换到nt 3605处的晚期特异性可变3'剪接位点。为了研究这些外显子剪接增强子的序列特异性,将各种突变的SE1或SE2元件连接到dsx前体mRNA上,并在体外测试它们对dsx前体mRNA剪接的刺激作用。在SE1或SE2中潜在的ASF/SF2结合位点及其周围将U残基替换为A或G残基会导致剪接增强子活性显著降低。然而,两个增强子中的G-to-U替换影响最大,将剪接降低到接近对照水平。进一步的体外分析表明,SE2介导的剪接增强可被过量的未标记SE2 RNA竞争,这表明HeLa核提取物中的SE2活性是由反式作用因子介导的。紫外线交联加免疫沉淀试验表明,野生型SE1和SE2 RNA都能直接与纯化的HeLa SR蛋白SRp30a(ASF/SF2)、SRp55和SRp75结合。紫外线交联实验还鉴定出一种23 kDa的蛋白,它能与SE2结合,但不能与SE1结合。这种蛋白存在于HeLa核提取物和S100提取物中,但不存在于SR蛋白制剂中,这表明它不是一种典型的SR蛋白。具有最小剪接增强子活性的突变SE元件(含有G-to-U突变)对这些蛋白的结合能力也非常弱,这强烈表明这些蛋白的结合是剪接增强子功能所必需的。